Results 101 to 110 of about 103,365 (348)

Unraveling the obesity–asthma link: A new horizon with glucagon-like peptide-1 receptor agonists in a complex intersection of metabolism and airway disease

Journal of International Medical Research
The global prevalence of obesity and asthma has escalated in parallel over recent decades, presenting an intertwined public health crisis. Obesity not only increases the risk of asthma development but also complicates its clinical course by altering ...
Francesco Menzella, Marcello Cottini, Rory Chan   +2 more
doaj   +1 more source

Effect of Lixisenatide (Short-acting Glucagon-Like Peptide 1 Receptor Agonist) as an Add-on to Insulin in Lowering HbA1C among Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis [PDF]

, 2023
Ashwaq Ali Abusalem, Ahmad Raja Albalawi
openalex   +1 more source

What doesn't kill you makes you stranger: Dipeptidyl peptidase-4 (CD26) proteolysis differentially modulates the activity of many peptide hormones and cytokines generating novel cryptic bioactive ligands [PDF]

, 2019
Dipeptidyl peptidase 4 (DPP4) is an exopeptidase found either on cell surfaces where it is highly regulated in terms of its expression and surface availability (CD26) or in a free/circulating soluble constitutively available and intrinsically active form.
Aguilar-Pérez, Alexandra, Awad, Mohamed E., Eisa, Nada H., Elmansi, Ahmed M., Fulzele, Sadanand, Hamrick, Mark W., Herberg, Samuel, Hill, William D., Hussein, Khaled A., Isales, Carlos M., Kondrikov, Dmitry, McGee-Lawrence, Meghan E., Periyasamy-Thandavan, Sudharsan, Volkman, Brian F.   +13 more
core   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Glucagon-like peptide 1 receptor activation: anti-inflammatory effects in the brain

Neural Regeneration Research
The glucagon-like peptide 1 is a pleiotropic hormone that has potent insulinotropic effects and is key in treating metabolic diseases such as diabetes and obesity. Glucagon-like peptide 1 exerts its effects by activating a membrane receptor identified in
Yolanda Diz-Chaves, Zainab Maastor, Carlos Spuch, José Antonio Lamas, Lucas C González-Matías, Federico Mallo   +5 more
doaj   +1 more source

Glucagon-Like Peptide-1 Receptor–Atrial Natriuretic Peptide Axis [PDF]

Circulation: Cardiovascular Genetics, 2013
1. Kim M, Platt MJ, Shibasaki T, Quaggin SE, Backx PH, Seino S, Simpson JA, Drucker DJ. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med . 2013;19:567–575. 2. Newton-Cheh C, Larson MG, Vasan RS, Levy D, Bloch KD, Surti A, et al.
openaire   +1 more source

SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels [PDF]

, 2019
学位記番号 ...
Suga, Takayoshi, スガ, タカヨシ, 須賀, 孝慶   +2 more
core  

Pharmacokinetics, pharmacodynamics and safety of vutiglabridin after multiple oral administrations in healthy female and obese subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims Vutiglabridin (HSG4112) is a novel drug under clinical development for antiobesity treatment. This study aimed to evaluate the pharmacokinetics (PKs) and safety of vutiglabridin after multiple oral administrations in healthy Korean female and obese subjects and explore short‐term pharmacodynamic (PD) responses.
Sooyoun Lee, Hyun Chul Kim, Young Ran Yoon, In‐Jin Jang, Sang‐Ku Yoo, Kyung‐Sang Yu   +5 more
wiley   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Physiology and pharmacology of glucagon-like peptide-1 receptor

Фармация и фармакология (Пятигорск)
Modern approaches to the treatment of type 2 diabetes mellitus (T2DM) are aimed not only at glycemic control, but also at reducing cardiovascular risks.
D. V. Kurkin, D. A. Bakulin, E. I. Morkovin, V. I. Petrov, A. V. Strygin, K. N. Koryanova, Yu. V. Gorbunova, Yu. A. Kolosov, O. V. Ivanova, E. V. Pavlova, M. A. Dzhavakhyan, A. V. Zaborovsky, V. B. Saparova, I. E. Makarenko, R. I. Drai, A. N. Chumachenko   +15 more
doaj   +1 more source